Biogen

News

Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.

News

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

News

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.

News

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

News

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.